Postherpetic Neuralgia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Postherpetic Neuralgia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

“Delveinsight Business Research LLP”
DelveInsight’s “Postherpetic Neuralgia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Postherpetic Neuralgia (PHN) is a condition of recurring or persistent pain in an area of the body that has undergone an outbreak of herpes zoster virus (HZ), also known as the varicella-zoster virus, commonly termed shingles. It usually begins after shingles lesions (blisters) begin to crust over and heal but may occur in some patients who do not produce lesions.

Postherpetic Neuralgia is thought to be caused by the damage or alteration of nerves that register pain, pressure, and other sensory nerves (for example, touch) that occur when the reactivated HZ viruses travel down nerves to the skin. This process first begins when the virus causes chickenpox in an individual; the viruses can infect various dorsal root ganglia (nerve cells) as the chickenpox subsides. These viruses then can be reactivated, usually decades later, and produce shingle lesions. The reactivation of HZ is thought to be due to stress on the body from either another infection or an immunocompromised state.

Age is a high-risk factor for PHN. People over 60 years of age have about a 60% chance while people 70 or older have about a 75% chance of developing PHN after getting shingles.

Get FREE sample copy at:

Postherpetic Neuralgia Market

The Postherpetic Neuralgia market report also covers emerging drugs, current treatment practices, Postherpetic Neuralgia market share of the individual therapies, current and forecasted Postherpetic Neuralgia Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Postherpetic Neuralgia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Postherpetic Neuralgia Market Key Facts

  • According to L. Feller et al. 2017, about 10 to 15% of persons with HZ will develop PHN. This is uncommon under the age of 40 years, but in HZ-affected persons older than 60 years, it occurs in more than 50%. The more intense the mucocutaneous eruptions of HZ and the acute herpetic neuritis pain during the acute phase of HZ, the greater the frequency and intensity of the PHN.

  • According to a study conducted by Akira Ozawa et al. titled “Treatment of Postherpetic Neuralgia”, the incidence of PHN is about 5% among patients with herpes zoster in their 60s, reaching about 10% among those in their 80s. In Japan, people aged 65 years or older already number 23 million, accounting for 18% of the total population.

  • As per the study conducted by Jamie S Massengill et al. 2014, an estimated one million individuals in the US are diagnosed with herpes zoster (HZ; shingles) each year. Approximately 20% of these patients will develop postherpetic neuralgia (PHN).

Key Benefits of Postherpetic Neuralgia Market Report

  • Postherpetic Neuralgia market report provides an in-depth analysis of Postherpetic Neuralgia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Postherpetic Neuralgia market report will help in developing business strategies by understanding the Postherpetic Neuralgia Market trends & developments, key players, and future market competition that will shape and drive the Postherpetic Neuralgia market in the upcoming years.

  • The Postherpetic Neuralgia market report covers Postherpetic Neuralgia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Postherpetic Neuralgia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Postherpetic Neuralgia Market

Postherpetic Neuralgia market size is anticipated to increase during the study period owing to the rise in the number of Prevalent cases of PHN patients in 7MM. Extensive research and development activities of pharmaceutical companies involved in developing therapies for Postherpetic Neuralgia, increasing awareness, and changing lifestyle will also impact the market.

The Postherpetic Neuralgia market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Postherpetic Neuralgia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Postherpetic Neuralgia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Postherpetic Neuralgia Epidemiology

The Postherpetic Neuralgia epidemiology section covers insights about the historical and current Postherpetic Neuralgia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Postherpetic Neuralgia Epidemiology Segmentation – 

  • Prevalent cases of Postherpetic Neuralgia

  • Drug-Treatable Cases of Postherpetic Neuralgia

  • Diagnosed Cases of Postherpetic Neuralgia

  • Prevalent cases of Postherpetic Neuralgia

Postherpetic Neuralgia Drugs Uptake and Key Market Players

The Postherpetic Neuralgia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postherpetic Neuralgia market or expected to get launched in the market during the study period. The analysis covers Postherpetic Neuralgia market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamic of the Postherpetic Neuralgia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world. The current pipeline of Postherpetic neuralgia is limited, as only a few companies are working on Postherpetic Neuralgia. This provides an opportunity for other companies to enter the market and grab a significant market share.

Postherpetic Neuralgia Companies:
Lateral Pharma
Novartis Pharmaceuticals
Teva Branded Pharmaceutical
And many others.

Postherpetic Neuralgia Therapies covered in the report include:
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Postherpetic Neuralgia Competitive Intelligence Analysis

4. Postherpetic Neuralgia Market Overview at a Glance

5. Postherpetic Neuralgia Disease Background and Overview

6. Postherpetic Neuralgia Patient Journey

7. Postherpetic Neuralgia Epidemiology and Patient Population

8. Postherpetic Neuralgia Treatment Algorithm, Current Treatment, and Medical Practices

9. Postherpetic Neuralgia Unmet Needs

10. Key Endpoints of Postherpetic Neuralgia Treatment

11. Postherpetic Neuralgia Marketed Products

12. Postherpetic Neuralgia Emerging Therapies

13. Postherpetic Neuralgia Seven Major Market Analysis

14. Attribute Analysis

15. Postherpetic Neuralgia Market Outlook (7 major markets)

16. Postherpetic Neuralgia Access and Reimbursement Overview

17. KOL Views on the Postherpetic Neuralgia Market.

18. Postherpetic Neuralgia Market Drivers

19. Postherpetic Neuralgia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight – 
Postherpetic Neuralgia Pipeline Insights
Postherpetic Neuralgia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postherpetic Neuralgia market.

Lennox Gastaut Syndrome Market
DelveInsight’ s “Lennox Gastaut Syndrome Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Lennox Gastaut Syndrome market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States